Reply to: Early white matter changes on diffusion tensor imaging in amyotrophic lateral sclerosis. by Gabel, Matt C. et al.
REPLY TO LETTER
Reply to: Early white matter changes on diffusion tensor
imaging in amyotrophic lateral sclerosis
Matt C. Gabel1 , Rebecca J. Broad2, Alexandra L. Young3, Sharon Abrahams4, Mark E. Bastin4,
Laura H. Goldstein5, Martin R. Turner6,7 , Mara Cercignani1 & P. Nigel Leigh2
1Department of Neuroscience, Clinical Imaging Sciences Centre, Brighton and Sussex Medical School, University of Sussex, Brighton, East Sussex,
UK
2Department of Neuroscience, Trafford Centre, Brighton and Sussex Medical School, University of Sussex, Brighton, East Sussex, UK
3Centre for Medical Image Computing, Department of Computer Science, University College London, Gower Street, London, WC1E 6BT, UK
4Department of Psychology, School of Philosophy, Psychology & Language Sciences, Euan MacDonald Centre for Motor Neurone Disease
Research, University of Edinburgh, Edinburgh, UK
5Department of Psychology, Institute of Psychiatry, Psychology, and Neuroscience, King’s College London, London, UK
6Wellcome Centre for Integrative Neuroimaging, FMRIB, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
7Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
Correspondence
Matt C. Gabel, Trafford Centre, Brighton and
Sussex Medical School, Brighton BN1 9RY,
UK. Tel: +44 1273 877261; E-mail:
m.gabel@bsms.ac.uk
Funding Information
No funding information provided.
Received: 25 May 2020; Accepted: 28 May
2020
Annals of Clinical and Translational
Neurology 2020; 7(7): 1266–1267
doi: 10.1002/acn3.51107
We thank Dr Finsterer and colleagues for their com-
ments1 on our paper.2 They raise a number of interesting
points.
Firstly, they suggest that we should differentiate between
patients with bulbar and limb onset. In our sample, 15%
had bulbar onset and 85% limb onset (of the 143 subjects
where this information was available), indicating that the
samples overall were reasonably representative of amy-
otrophic lateral sclerosis (ALS) clinic cohorts.
However, our data-driven approach requires large sam-
ple sizes to disentangle the temporal heterogeneity of
ALS. We would be underpowered in this study to analyze
small subgroups, including bulbar onset versus limb
onset, especially as we do not know of any specific imag-
ing biomarker that reliably discriminates between these
categories.
Secondly, Dr Finsterer and colleagues suggest that peo-
ple with familial ALS might have a differing disease
course from those with sporadic ALS. Unfortunately,
detailed and consistent data on the family history were
not available for all cohorts at time of analysis, and ethics
approval to carry out comprehensive genetic testing was
not sought for cohorts E, F, K, and N. However, the same
concerns about small group analyses apply: we conclude
that, lacking definitive genetic data on all subjects, sub-
group analysis (whether by history or genetic testing)
would not enhance the results of our study.
Thirdly, they suggest that we should have included dis-
ease duration as a predictor. We do not consider that ALS
disease duration per se as measured in absolute terms (e.g.
years and months) is particularly informative for this study,
as the progression rate of ALS is extremely variable. We
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consider that disease ‘intensity’ (i.e. severity in relation to
duration) is the most pertinent measure in this context. As
stated in the text, disease severity at the time of scanning
was assessed by ALSFRS-R. We also emphasize that the
modeling process requires that we include subjects at as
many different stages of the disease as possible.
Finally, Finsterer and colleagues question our inclusion of
the inferior longitudinal fasciculus (ILF) as a white matter
tract of interest in ALS. However, as cited in our study, recent
tractography techniques have clearly demonstrated correla-
tions between performance in cognitive tasks and diffusion
tensor imaging changes in the ILF in ALS.3 The ILF has also
been shown to be involved in emotional dysfunctions4 and
verbal fluency impairments5 in ALS, and reduced white mat-
ter integrity of the ILF has been found in ALS patients with
the C9orf72 repeat expansion.6
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